Molecular classification of aggressive lymphomas-past, present, future

Area of Science:

• Hematology
• Oncology
• Genomics

Background:

• Aggressive large B-cell lymphomas (LBCLs) are common, yet exhibit significant clinical and molecular diversity.
• Despite advances in diagnosis and molecular understanding, patient outcomes for LBCLs have seen limited improvement.
• Existing classification systems aim to refine diagnoses, explore heterogeneity, predict prognosis, and identify therapeutic targets.

Purpose of the Study:

• To highlight how high-throughput technologies enhance the molecular understanding of LBCLs.
• To provide examples of rationally designed targeted treatments for personalized LBCL therapy.
• To discuss the potential of new approaches to improve patient perspectives.

Main Methods:

• Comprehensive genomic studies identifying genetically defined LBCL subtypes.
• Integration of multiomics studies.
• Application of single-cell technologies.

Main Results:

• Discovery of genetically defined LBCL subtypes with prognostic value.
• Insights into the mechanisms of lymphomagenesis.
• Identification of potential rational therapeutic targets.

Conclusions:

• Genomic insights are paving the way for patient-tailored treatments in LBCL.
• Multiomics and single-cell technologies promise a more granular understanding of LBCL biology.
• Personalized treatment approaches hold the potential to improve future patient outcomes.